|
Real-time Estimate
Cboe BZX
11:13:45 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 15.91 USD | +1.66% |
|
+5.08% | -31.15% |
| 10-19 | Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi | MT |
| 10-14 | Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203 Million | DJ |
Company Valuation: Ultragenyx Pharmaceutical Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,732 | 3,248 | 3,926 | 3,882 | 2,215 | 1,538 | - | - |
| Change | - | -43.33% | 20.88% | -1.13% | -42.94% | -30.55% | - | - |
| Enterprise Value (EV) 1 | 4,992 | 2,500 | 3,149 | 3,137 | 1,478 | 1,111 | 1,007 | 1,046 |
| Change | - | -49.91% | 25.96% | -0.39% | -52.88% | -24.81% | -9.41% | 3.88% |
| P/E | -12.6x | -4.58x | -5.8x | -6.69x | -3.95x | -4.2x | -27.3x | -289x |
| PBR | 6.32x | 9.23x | 12.8x | 15.2x | -27.8x | -7.18x | -66.7x | 10.5x |
| PEG | - | -0.1x | 0.3x | 0.3x | 0.54x | 0.1x | 0.3x | 3.2x |
| Capitalization / Revenue | 16.3x | 8.94x | 9.04x | 6.93x | 3.29x | 2.02x | 1.54x | 1.32x |
| EV / Revenue | 14.2x | 6.88x | 7.25x | 5.6x | 2.2x | 1.46x | 1.01x | 0.89x |
| EV / EBITDA | -13.5x | -3.96x | -5.8x | -6.27x | -2.96x | -2.87x | 51.6x | 6.36x |
| EV / EBIT | -13.1x | -3.85x | -5.53x | -5.85x | -2.76x | -2.67x | -25.5x | 16x |
| EV / FCF | -12.1x | -5.03x | -6.07x | -7.44x | -3.13x | 3.21x | 76.4x | 12.1x |
| FCF Yield | -8.25% | -19.9% | -16.5% | -13.4% | -31.9% | 31.1% | 1.31% | 8.26% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -6.7 | -10.12 | -8.25 | -6.29 | -5.83 | -3.727 | -0.5722 | -0.0541 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 351.4 | 363.3 | 434.2 | 560.2 | 673 | 760.2 | 997 | 1,169 |
| EBITDA 1 | -368.5 | -630.7 | -543.2 | -500.4 | -500 | -387.7 | 19.5 | 164.5 |
| EBIT 1 | -381.7 | -648.9 | -569.2 | -536 | -535 | -415.5 | -39.47 | 65.2 |
| Net income 1 | -454 | -707.4 | -606.6 | -569.2 | -575 | -390.5 | -72.28 | -1.155 |
| Net Debt 1 | -740.2 | -747.8 | -777.1 | -745 | -737 | -426.9 | -531.5 | -492.4 |
| Reference price 2 | 84.09 | 46.33 | 47.82 | 42.07 | 23.00 | 15.65 | 15.65 | 15.65 |
| Nbr of stocks (in thousands) | 68,162 | 70,106 | 82,106 | 92,275 | 96,305 | 98,289 | - | - |
| Announcement Date | 2/10/22 | 2/16/23 | 2/15/24 | 2/13/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.2x | 1.46x | -2.87x | -.--% | 1.54B | |
| 37.06x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.49x | 18.27x | 2.02% | 635B | |
| 36.46x | 8.38x | 17.33x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.68x | 13.94x | 2.81% | 295B | |
| 22.43x | 4.53x | 12.94x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 26.13x | 6.48x | 16.54x | 1.9% | 400.52B | |
| Weighted average by Cap. | 35.21x | 8.29x | 20.39x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RARE Stock
- Valuation Ultragenyx Pharmaceutical Inc.
Select your edition
All financial news and data tailored to specific country editions
